Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued
Reference number: GID-TA10764
We are continuing to face significant capacity challenges and will be delaying the development of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022.